Furthermore, increased SLC35A2 expression was noted in uterine carcinosarcoma (UCS), brain lower grade glioma (LGG), adrenocortical carcinoma (ACC), and pheochromocytoma and paraganglioma (PCPG); however, the differences were not statistically significant. This evidence concerns the gene SLC35A2 and pheochromocytoma.